Xinxiang Tuoxin Pharmaceutical Co.Ltd. Working Capital to Net Assets Ratio
Xinxiang Tuoxin Pharmaceutical Co.Ltd. working capital to net assets ratio. Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has a Working Capital to Net Assets ratio of 29.8% as of March 2026. Working capital of CN¥439.09 Million (current assets of CN¥580.41 Million minus current liabilities of CN¥141.32 Million) is measured against net assets of CN¥1.47 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2019–2025)
Working capital to net assets ratio of Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2025. This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 29.8%, reflecting working capital of CN¥439.09 Million against net assets of CN¥1.47 Billion CNY. See Xinxiang Tuoxin Pharmaceutical Co.Ltd. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Working Capital to Net Assets Ratio by Year (2019–2025)
Xinxiang Tuoxin Pharmaceutical Co.Ltd. working capital to net assets ratio by year from 2019 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Xinxiang Tuoxin Pharmaceutical Co.Ltd. assets under control.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 29.6% | CN¥438.98 Million | CN¥1.48 Billion | CN¥584.95 Million | CN¥145.97 Million | ▼ -3.4 pp |
| 2024 | 33.0% | CN¥511.69 Million | CN¥1.55 Billion | CN¥677.01 Million | CN¥165.32 Million | ▼ -6.2 pp |
| 2023 | 39.1% | CN¥627.66 Million | CN¥1.60 Billion | CN¥822.17 Million | CN¥194.51 Million | ▼ -3.7 pp |
| 2022 | 42.9% | CN¥590.04 Million | CN¥1.38 Billion | CN¥1.01 Billion | CN¥423.96 Million | ▼ -6.5 pp |
| 2021 | 49.4% | CN¥542.16 Million | CN¥1.10 Billion | CN¥796.76 Million | CN¥254.60 Million | ▲ +50.5 pp |
| 2020 | -1.1% | CN¥-5.59 Million | CN¥490.87 Million | CN¥414.91 Million | CN¥420.50 Million | ▲ +1.9 pp |
| 2019 | -3.1% | CN¥-11.78 Million | CN¥383.11 Million | CN¥310.29 Million | CN¥322.08 Million | — |